IN8bio, Inc. Common Stock
INABIN8bio, Inc. (INAB) is a clinical-stage biotechnology company focused on developing innovative cell therapies for the treatment of resistant and hard-to-treat cancers. The company leverages its proprietary gamma delta T cell platform to engineer and enhance immune responses against tumors, aiming to improve patient outcomes through its advanced immunotherapy approaches.
Company News
IN8bio reported financial results and highlighted preclinical data on INB-619, a novel gamma-delta T cell engager, demonstrating potential for deep B cell depletion with minimal adverse effects. The company expanded its INB-100 Phase 1 clinical trial to The Ohio State University and continues advancing its T cell therapy platform.
Shares of PriceSmart, Inc. (NASDAQ: PSMT) rose sharply in today’s pre-market trading as the company posted better-than-expected earnings for its second quarter. The company reported quarterly earnings of $1.31 per share, beating market estimates of $1.25 per share. PriceSmart’s quarterly sales came in at $1.29 billion versus expectations of ...
Get the latest financial updates and insights with Wall Street Breakfast's daily podcast available on Seeking Alpha, iTunes, and Spotify.
IN8bio, Inc. (INAB) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Penny stocks under $5 to watch this week. The post Best Penny Stocks To Buy Today? 4 To Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
